Back to search

Article

Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

2007-01-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7505e410-ba63-5d5d-b862-9d1a7814d394
DOI
10.1016/s0093-3619(08)70664-6
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesDOI 10.1016/s0093-3619(08)70664-6
The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation studySemantic proximity
Engineered T cells for cancer therapySemantic proximity
Engineered T cells for anti-cancer therapySemantic proximity
Strategies to genetically engineer T cells for cancer immunotherapySemantic proximity
Genetically engineered T cells for the treatment of cancerSemantic proximity
Clinical application of genetically modified T cells in cancer therapySemantic proximity
Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid TumorsSemantic proximity
Genetically engineered T cells for cancer immunotherapySemantic proximity
Ex vivo gene transfer for improved adoptive immunotherapy of cancerSemantic proximity
Genetically modified T cells in cancer therapy: opportunities and challengesSemantic proximity
Genetically engineered mouse models of cancer reveal new insights about the antitumor immune responseSemantic proximity
Modeling the cancer patient with genetically engineered miceSemantic proximity
Select a neighboring publication to make it the new centre.